

Full Length Article

Deletion of nicotinic acetylcholine receptor alpha9 in mice resulted in altered bone structure



Lisa Baumann^a, Vivien Kauschke^a, Anna Vikman^b, Lutz Dürselen^b, Gabriela Krasteva-Christ^c, Marian Kampschulte^d, Christian Heiss^e, Kathleen T. Yee^f, Douglas E. Vetter^f, Katrin Susanne Lips^{a,*}

^a Experimental Trauma Surgery, Justus-Liebig-University Giessen, Aulweg 128, 35392 Giessen, Germany

^b Institute of Orthopaedic Research and Biomechanics, Center for Trauma Research, Ulm University Medical Centre, Helmholtzstrasse 14, 89081 Ulm, Germany

^c Institute of Anatomy and Cell Biology, Saarland University, Kirrberger Straße, 66421 Homburg, Germany

^d Laboratory of Experimental Radiology, Justus-Liebig-University Giessen, Schubertstrasse 81, 35392 Giessen, Germany

^e Department of Trauma, Hand, and Reconstructive Surgery Giessen, University Hospital of Giessen-Marburg, Rudolf-Buchheim-Str. 7, 35392 Giessen, Germany

^f Department of Neurobiology and Anatomical Sciences, University Mississippi Medical Center, Jackson, MS, USA

ARTICLE INFO

Keywords:

Bending stiffness

Micro-CT

Connexin-43

Collagen 1 α 1

nAChR α 10

Non-neuronal cholinergic system

ABSTRACT

Alterations in bone strength and structure were found in knockout (KO) mouse strains with deletion of several acetylcholine receptors. Interestingly, the expression of the nicotinic acetylcholine receptors (nAChR) subunit α 10 was down-regulated in osteogenic differentiated mesenchymal stem cells of patients with osteoporosis whereas the expression of subunit α 9 was not altered. Since nAChR subunits α 9 and α 10 are often combined in a functional receptor, we analyzed here the bone of adult female KO mice with single deletion of either nAChR alpha9 (α 9KO) or alpha10 (α 10KO).

Biomechanical testing showed a significant decrease of bending stiffness and maximal breaking force in α 9KO compared to their corresponding wild type mice. Furthermore, an increase in trabecular pattern factor (Tb.Pf) and structure model index (SMI) was detected by μ CT in α 9KO indicating reduced bone mass. On the mRNA level a decrease of Collagen 1 α 1 and Connexin-43 was measured by real-time RT-PCR in α 9KO while no alteration of osteoclast markers was detected in either mouse strain. Using electron microscopy we observed an increase in the number of osteocytes that showed signs of degeneration and cell death in the α 9KO compared to their wild type mice, while α 10KO showed no differences.

In conclusion, we demonstrate alterations in bone strength, structure and bio-marker expression in α 9KO mice which imply the induction of osteocyte degeneration. Thus, our data suggest that nAChR containing the α 9 subunit might be involved in the homeostasis of osteocytes and therefore in bone mass regulation.

1. Introduction

Alterations in bone strength and structure were found in knockout (KO) mice with deletion of several acetylcholine receptors [1–3]. Nicotinic acetylcholine receptors (nAChR) are pentameric ion channels built by a combination of alpha (α 1– α 10) and beta (β 1– β 4) subunits or solely by alpha subunits in the case of homopentamers (α 7, α 9) or as alpha-heteropentamer (α 9 α 10) [4]. Electrophysiological analysis of combined α 9 and α 10 subunits demonstrated 100-fold more functional receptors compared to α 9 homopentamers [5,6]. nAChR α 9 α 10 are

activated by acetylcholine, but not by nicotine. In addition, they are sensitive to muscarine and atropine and show therefore mixed ionotropic and metabotropic profile [6]. The α 9 α 10 nAChR was first identified in the outer hair cells of cochlea where it is involved in auditory signaling [5]. Additionally, the α 9 α 10 nAChR are associated with chronic pain signaling and therefore seem to be a promising target for analgesic medications [7]. Moreover α 9 α 10 nAChR were found in immune cells (B-cells, T-cells) where they lack single cell responses to acetylcholine (ACh) typically expected for ionotropic receptors [8,9]. The α 9 α 10 nAChR provokes long-term intracellular cascades by

* Corresponding author at: Experimental Trauma Surgery, Justus-Liebig-University Giessen, Aulweg 128, 35392 Giessen, Germany.

E-mail addresses: Lisa.Baumann@med.uni-giessen.de (L. Baumann), Vivien.Kauschke@chiru.med.uni-giessen.de (V. Kauschke), Lutz.Duerselen@uni-ulm.de (L. Dürselen), Gabriela.Krasteva-Christ@uks.eu (G. Krasteva-Christ), Marian.Kampschulte@radiol.med.uni-giessen.de (M. Kampschulte), Christian.Heiss@chiru.med.uni-giessen.de (C. Heiss), kyee@umc.edu (K.T. Yee), dvetter@umc.edu (D.E. Vetter), Katrin.S.Lips@chiru.med.uni-giessen.de (K.S. Lips).

<https://doi.org/10.1016/j.bone.2018.11.003>

Received 9 May 2018; Received in revised form 17 October 2018; Accepted 5 November 2018

Available online 07 November 2018

8756-3282/ © 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

interacting with calcium stores in response to inflammatory triggers [8,9]. Receptors containing one or both $\alpha 9$ and $\alpha 10$ subunits were found in several neuronal and non-neuronal tissues e.g. brain regions [10], breast tumors [11,12], keratinocytes [13], and bronchial epithelial cells [14]. In these systems an involvement in inner (mitochondrial-derived) apoptotic pathways [10], stimulation of proliferation [11,14], and a cell-type specific transformation into cancerogenic cells [12] is indicated. The role of $\alpha 9$ nAChR in skin keratinocytes has been analyzed in more detail. nAChR $\alpha 9$ control cell shape, cytoplasm mobility, wound re-epithelialization, proper migration as well as cell-cell and cell-matrix contacts via phosphorylation of specific adhesion molecules [13].

nAChR subunit $\alpha 9$ mRNA was found to be highly expressed in chondrocytes and/or osteoblasts of the developing labyrinthine bone as well as in bone marrow cells of juvenile and adult rats as determined by in-situ hybridization [15]. Expression of nAChR subunits $\alpha 9$ and/or $\alpha 10$ was also described in hematopoietic stem cells and several phases of differentiating blood cells, including leucocytes, monocytes, and bone marrow macrophages [1,2,8]. In addition, bone marrow contains amongst others endothelial and smooth muscle cells, nerve fibers, adipocytes, and mesenchymal stem cells (MSC) that are precursors of osteoblasts, chondrocytes, and adipocytes. Zablotni et al. reported the expression of $\alpha 9$ and $\alpha 10$ subunits in female native MSC and in osteogenic differentiated MSC of both genders [16]. An up-regulation of $\alpha 10$ mRNA level was detected in osteoblasts of healthy compared to osteoporotic donors [16]. Both $\alpha 9$ and $\alpha 10$ nAChR mRNA were found in native and osteogenic differentiated murine osteoblast from the cell line MC3T3, in osteoblastic human osteosarcoma cell line SAOS-2 [17], in rat maxilla [18,19] whereas in osteocytes only the $\alpha 10$ subunit and in murine tibia the $\alpha 9$ subunit were detected [20].

To further investigate the functional role of the nAChR subunits $\alpha 9$ and $\alpha 10$ in bone, we analyzed mice carrying a global constitutive knockout (KO) of the single subunits. Recently it was shown that deletion of mAChR M3 and nAChR $\alpha 2$ in mice resulted in bone alterations similar to osteoporosis [2,3]. Here, we used biomechanical, radiological, histological, cell and molecular biological methods as well as transmission electron microscopy to analyze whether either the $\alpha 9$, $\alpha 10$ or both subunits are involved in alterations of bone structure, strength and homeostasis.

2. Materials and methods

2.1. Mice

Female mice with a deletion of nAChR subunit $\alpha 9$ ($n = 8$, 129S-*Chrna9*^{tm1Bedv/J}) or subunit $\alpha 10$ ($n = 8$, 129S4-*Chrna10*^{tm1Bedv/Mmucd}) and their corresponding wild type mice ($\alpha 9$ $n = 8$, $\alpha 10$: $n = 8$) were euthanized at the age of 16–20 weeks according to the recommendations of the AVMA Guidelines for the Euthanasia of Animals. Afterwards the bones were extracted for subsequent analysis. The breeding pair was a kind gift of Dr. Douglas E. Vetter [21,22]. The mice were bred in the animal facility of the Justus-Liebig-University Giessen with a 12 h day and night cycle and free access to water and food. All animal experiments were performed in accordance with the ARRIVE guidelines and the EU Directive 2010/63/EU and had been declared to the Animal Welfare Officer of the Justus-Liebig-University (Registration No.: M_492 and M_521, Giessen, Germany). A separate set of male and female $\alpha 9$ KO ($n = 18$) and $\alpha 9$ WT ($n = 6$) at an age of 17 to 22 weeks were used for mouse hang test at the UMMC Animal Behavior Core Facility.

2.2. Mouse hang test

A 55 cm long, 2 mm thick metallic wire was secured to two vertical poles. The wire was stretched across the vertical poles approximately 40 cm above a thick layer of standard bedding into which the mouse

falls if they release their grip on the wire. The “longest suspension time” method was used, and the test was run as follows. 1. The mouse was handled by the tail and allowed to grasp the middle of the wire with its forelimbs. The mouse was then gently lowered so that its hind paws did not grasp the wire. 2. The tail was then released while the mouse grasped the wire. Upon release, a timer was started. 3. The time until the mouse completely releases its grasp and falls into the bedding was recorded. A fixed maximum time for hanging without falling was 180 s. 4. If the mouse did not reach the maximum time limit, it was given three trials per session, with a 1 min recovery period between trials. The maximum hang time was recorded as the longest single hang. In all cases, this was the first attempt. If a mouse reached the maximum time limit, the testing was considered complete. Mice underwent only one session with a maximum of three trials.

2.3. Biomechanical analysis of femoral bones

After extraction of left femur it was covered with a 0.9% NaCl moistened pad and stored at -20°C . Prior to the measurement, the femur was thawed and the proximal part fixed in an aluminum cylinder 8 mm in diameter using iCEM self-adhesive glue (Heraeus-Kulzer, Hanau, Germany). The aluminum cylinder was fixed in a hinge joint of a material testing machine (Zwick Z10, Ulm, Germany), serving as the proximal support for the bending test whereas the distal end of the femur was rested unfixed on a distal bending support with a distance of 6.5 mm to the force transducer. After two test cycles the bone was broken in the third cycle and the data were collected by testXpertII software (Version 3.2, Zwick). Using the load-deformation curve, the maximal breaking force and bending stiffness were calculated as described previously [23].

2.4. Micro-computed tomography

The right femur and vertebra L1 were fixed in 4% phosphate buffered paraformaldehyde, washed in 0.1 M phosphate buffer (pH 7.3) and scanned with a high-resolution micro-computed tomograph (Micro-CT 1173, SkyScan, Kontich, Belgium) at 5.69 μm voxel size and 16 bit gray scale range as described earlier [24]. To define volume of interest (VOI) of distal metaphysis, the growth plate was used as a reference level. The trabecular area of the femur metaphysis including 309 slices (1.753 mm) was measured with a distance of 0.216 mm from reference level. Cortical distal and mid diaphysis, each 80 slices (0.45 mm), were examined distantly at 2.179 mm and 5.497 mm from reference level. According to the manual “Structural parameters measured by the SkyscanTM CT-analyzer software” and the review of Bouxsein et al., regions of interest (ROIs) were selected with a short distance to endocortical surface [25]. The whole trabecular area of vertebral body was manually scanned excluding primary spongiosa and cartilage. BMD and TMD measurement was performed using calibrating phantoms with defined calcium hydroxyapatite density.

Regarding the cortical regions of femur's diaphysis, the following parameters [25] were calculated: total cross-sectional area inside the periosteal envelope (Tt.Ar), cortical bone area (Ct.Ar), cortical area fraction (Ct.Ar/Tt.Ar), cortical thickness (Ct.Th), total porosity (Po.tot) and the tissue mineral density (TMD). The following parameters were calculated for the trabecular bone of femur and vertebra L1: bone volume fraction (BV/TV), specific bone surface (BS/BV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular pattern factor (Tb.Pf), structure model index (SMI), and bone mineral density (BMD). 3D-color coded models of trabecular thickness were generated with CTvox (version, 3.3.0r1403 (64bit), SkyScan).

2.5. Histology, enzyme- and immunohistochemistry, and histomorphometry

After extraction, vertebrae L3 were fixed in 4% phosphate buffered paraformaldehyde, washed carefully in 0.1 M phosphate buffer

(pH 7.3), decalcified in 10% ethylenediaminetetraacetate (EDTA), and dehydrated with a graded series of ethanol and embedded in paraffin. Dewaxed 5 µm thick sections were used for enzyme histochemical staining of alkaline phosphatase (ALP) and tartrate resistant acid phosphatase (TRAP) as described previously [24]. For immunohistochemistry dewaxed sections were preincubated in 3% H₂O₂ in Tris-NaCl buffer (TBS) with 0.025% Triton-X for 5 min to block endogenous peroxidase. Primary antibodies against (i) sclerostin (1:100 diluted, abcam, Cambridge, UK) and (ii) Connexin-43 (Cx43) (1:100 diluted, Thermo Fisher Scientific, Waltham, MA, USA) were incubated overnight in dilution buffer (Dako, Glostrup, Denmark) at 4 °C. Thereafter sections were processed with (i) an anti-rabbit secondary antibody that is conjugated with HRP labeled polymer (Dako EnVision) or (ii) a goat anti-rabbit secondary antibody (diluted 1:500, Vector, Burlingame, CA, USA) for 30 min. A 5 min incubation with 3,3'-diaminobenzidine substrate-chromogen (Dako) staining of sclerostin was completed. Immunostaining for Cx43 was accomplished using a 30 min incubation with an avidin and biotin peroxidase system (Vectastain Elite ABC, Vector) and 5 min incubation using a substrate kit for peroxidase (Nova Red, Vector). Nuclei were counterstained with hematoxylin and the sections were coverslipped with Depex (Serva, Heidelberg, Germany).

Vertebrae L1 were also fixed in 4% paraformaldehyde and washed with phosphate buffer, before they were dehydrated with a graded series of ethanol and then embedded in Technovit 9100 (Heraeus Kulzer, Hanau, Germany) as described in detail by the manufacturer's protocol. Sections with a thickness of 5 µm were histologically stained with Kossa-van-Gieson method as described earlier [24]. Staining with silver nitrate solution (Sigma-Aldrich, Steinheim, Germany) and Gieson's mixture (Chroma/Waldeck, Münster, Germany) was used to differentiate between mineralized bone matrix and osteoid. Photos were taken with microscope Axiophot-2 (Zeiss, Jena, Germany) fitted with digital camera (Leica DC 500, Leica, Bensheim, Germany) and corresponding software Leica IM1000 (Version 4.0, Leica Microsystems, Cambridge, UK).

The trabecular bone of vertebral body was analyzed histomorphometrically using Adobe Photoshop CS5 (Adobe, San Jose, CA, USA) and traphisto software [26]. We measured the relative perimeter of ALP staining (ALP.Pm/B.Pm), the number of osteoclasts per bone perimeter (N.Oc/B.Pm), the relative osteoclast perimeter (Oc.Pm/B.Pm), the number of sclerostin positive osteocytes per bone area (Scl.Ot/B.Ar), and the relative osteoid area (O.Ar/B.Ar).

2.6. Real-time reverse transcriptase polymerase chain reaction (real-time RT-PCR)

Vertebrae Th10 was transferred into RNA-later (Ambion Applied Biosystems, Foster City, CA, USA) directly after euthanasia. For RNA isolation tissue was homogenized in lysis buffer (Qiazol, Qiagen, Hilden, Germany) with a vibratory mill (MM400, Retsch, Haan, Germany). Then 200 µL of chloroform (Sigma-Aldrich, St.-Louis, MO, USA) were added and the samples were centrifuged for 15 min at 4 °C. RNA was collected from the aqueous phase and mixed with the same amount of 70% ethanol. The solution was transferred into RNeasy Mini Spin Columns (RNeasy Lipid Tissue Mini Kit, Qiagen) and centrifuged to enable the binding of RNA to the column membrane. RNA was washed with several buffers (kit component, RNeasy Lipid Tissue Mini Kit, Qiagen) and eluted with RNase-free water. The RNA concentration and purity were determined using a Nanodrop photometer (ND-1000, Nanodrop Technologies, Wilmington, NC, USA). RNA was stored at –80 °C before reverse transcription into cDNA. For elimination of contaminations with genomic DNA 750 ng RNA was incubated with 3 µL wipeout buffer (Qiagen) at 42 °C in a thermo cycler (TC-3000, Techne, Bibby Scientific, USA). Afterwards reverse transcriptase (RT), buffers, RT primer mix (Quantitect Reverse Transkriptase Kit, Qiagen) were added and incubated for 30 min at 42 °C. After inactivation of reverse transcriptase for 3 min at 95 °C, samples were stored at –20 °C.

Table 1
Primer pairs used for real-time RT-PCR.

Primer	Sequence	Length [bp ^a]	GenBank ID (accession)
ALP ^a	for ^b TCAGCTAATGCACAATATCAAGG rev ^c TCCACATCAGTTCTGTCTTCG	87	NM_007431.2
Col 1α1 ^d	for TGGCATCCCTGGACAGCCTG rev ATGGGGCCAGGACGAAAC	144	NM_007742.3
CtsK ^e	for GAGGCGGCTATATGACCACT rev CTTTGCCGTGGCGTTATACA	119	NM_007802.3
Cx43 ^f	for TGCTTCCTCTCACGTCCAC rev CGCGATCCTTAACGCCCTTG	127	NM_010288.3
SOST ^g	for GCCTCCTCTGAGAACAACC rev GGCAATGGGCGCTCTGTC	143	NM_024449.6
βactin	for TGTTACCAACTGGGACGACA rev GGGGTGTTGAAGGTCTCAA	165	NM_007393.3

^a ALP: alkaline phosphatase.

^b for: forward.

^c rev: reverse.

^d Col1α1: Collagen 1α1.

^e CtsK: Cathepsin K.

^f Cx43: Connexin 43.

^g SOST: sclerostin.

^h bp: base pairs.

Real-time RT-PCR was performed using the Quantifast Sybr Green PCR Kit (Qiagen) according to the manufacturer's protocol. In brief, 0.2 µL of primers (Table 1, MWG Biotech, Ebersberg, Germany) with 0.8 µL RNase-free water and 5 µL of Quantifast Mastermix were diluted with 4 µL cDNA or RNase-free water to a volume of 10 µL. The dilution was transferred into capillaries (Roche, Mannheim, Germany), centrifuged 20 s at 2000 rpm and processed in a LightCycler 2.0 (Roche, Basel, Switzerland) with the following protocol: 5 min at 95 °C for denaturation and then 40 cycles of 10 s at 95 °C, 30 s at 60 °C for annealing and elongation. Afterwards the purity of PCR product was analyzed by melting curve analysis. Additionally, the following controls were performed during real-time RT-PCR: a) PCR without template, b) cDNA synthesis without addition of reverse transcriptase to control for contaminations with genomic DNA, c) determination of PCR efficiency and slope, and d) samples were analyzed in doublets. The value of the crossing point (CP) determines the point where the amplification curve crosses the vertical threshold line was normalized to the reference gene β-actin.

2.7. Transmission electron microscopy (TEM)

Samples of L4 vertebrae were immersion-fixed 6 h in a solution of 2% paraformaldehyde and 0.02% picric acid in phosphate buffer (pH 7.3), washed with 0.1 M cacodylate buffer and post-fixed for 2 h in 1% osmium tetroxide. Specimens were dehydrated in a graded series of ethanols followed by embedding in Epon (Serva, Heidelberg, Germany) Ultrathin sections were cut and then analyzed by TEM (EM 912, Zeiss, Oberkochen, Germany) equipped with a 2K slow-scan CCD camera. Pictures were scored by two blinded investigators. Osteocytes of 5 α9KO (n = 255), 5 α9WT (n = 177), 3 α10KO (n = 102), and 3 α10WT (n = 114) mice were evaluated. A score of 1 was given to healthy active osteocytes, 2 to osteocytes showing signs of cell degeneration and 3 to dying osteocytes. Degeneration of osteocytes was defined by the presence of at least two of the following characteristics: (i) extended pericellular space, (ii) folding of the cytoplasmic membrane, (iii) enlarged spaces between the nuclear membranes, and (iv) occurrence of enlarged vesicles.

2.8. Cell culture experiments

Osteoblasts were cultured from neonatal α9KO (n = 10) and α9WT (n = 7) C57BL/6J mice at day 1–4 according to the protocol of [27,28].

The neonatals were a kind gift of Dr. Claudia Dames (Institute of Medical Immunology, Charite – Universitätsmedizin Berlin, Germany). In brief, calvaria and long bones were incubated in 1 mg/mL collagenase (Capricorn Scientific, Ebsdorfergrund, Germany) and 4 mM ethylene diamine tetra acetic acid (EDTA) at 37 °C and centrifuged for 5 min at 1.500 g at 4 °C. Isolates were seeded in 24 well plates for 4 d at 37 °C and 5% CO₂ and passaged with 0.005% trypsin (Gibco, Life Technologies, Carlsbad, USA). Cells of passage 2 (13.441 cells/cm²) were used for osteogenic differentiation in α -minimum essential medium (MEM, Gibco) containing 10% fetal bovine serum (FBS, PAN Biotech, Aidenbach, Germany), 10⁻⁷ M dexamethasone (Sigma, St. Louis, MO, USA), 50 μ g/mL sodium L-ascorbate (Sigma), 2 \times 10⁻³ M β -glycero phosphate hydrate (Sigma), and gentamicin/amphotericin (Gibco) for 7 d. Then, mineralization was determined using the Senso-Lyte pNPP alkaline phosphatase assay (AnaSpec, Ferment, CA, USA) and collagen deposition was analyzed by a Picro-Sirius-Red assay (Abcam, Cambridge, UK). Subsequent histomorphometry calculated the area of positive collagen type 1 and 3 staining.

2.9. Statistical analysis

Statistical analyses were performed with SPSS software (version 23, SPSS Institute Inc., Chicago, USA). After testing for normal distribution by Kolmogorov-Smirnov test we used a *t*-test, Wilcoxon Rank Sum Test, or Kruskal-Wallis test followed by non-parametric Mann-Whitney test. Significance level was set at *p* value of < 0.05. Results were reported as mean \pm standard deviation and graphs were generated with Prism (version 6.02, GraphPad Software Inc., La Jolla, USA). nAChR α 9 and α 10 animals were not compared due to the genetic manipulation being on different mouse strains.

3. Results

3.1. Mouse hang test

To determine mouse muscle force and physical activity in vivo we performed the hang test which did not result in significant differences between α 9KO and α 9WT (*p* < 0.119; Fig. 1).




Fig. 1. Mouse hang test. Measurement of hanging time of α 9KO and α 9WT in seconds (s). α 9KO: knockout mice of nicotinic acetylcholine receptor subunit α 9; α 9WT: corresponding wild type mice of α 9KO.

3.2. Bone strength

The body weight of α 9KO (25.16 \pm 1.7 g) was significantly reduced compared to α 9WT (27.86 \pm 2.26 g, *p* < 0.05, Fig. 2A). The mid-diaphysal region of left femur was tested by a biomechanical three-point-bending test. The bending stiffness of α 9KO (2597.17 \pm 169.08 Nmm², Fig. 2B) as well as the maximal breaking force (9.33 \pm 0.41 N) were significantly decreased compared to α 9WT (2944.63 \pm 96.27 Nmm² and 10.65 \pm 0.61 N, each *p* < 0.001, Fig. 2C). No significant changes in body weight, bending stiffness and maximal breaking force were measured for α 10KO compared to the control α 10WT (Fig. 2).

3.3. Microarchitecture of cortical bone

The microstructure of cortical bone of mid (Fig. 3) and distal diaphysis (Fig. S1) of right femur was analyzed by μ CT. The Ct.Ar (Fig. 3A) as well as Tt.Ar (Fig. 3B) were significantly reduced in α 9KO (Ct.Ar 0.90 \pm 0.05 mm²; Tt.Ar 2.02 \pm 0.09 mm²) compared to α 9WT (Ct.Ar 1.01 \pm 0.04 mm², *p* < 0.05; Tt.Ar 2.26 \pm 0.17 mm², *p* < 0.01) while Ct.Ar/Tt.Ar showed no significant differences in the mid diaphysis (Fig. 3C). No changes were observed for the α 10KO and WT. Similar results were measured in the distal diaphysis of right femur (Fig. S1A–C). In addition, we measured significantly decreased total porosity (Po.tot) in α 9KO (0.06 \pm 0.08%) compared to α 9WT (0.18 \pm 0.13%, *p* < 0.05). Ablation of the α 10 subunit did not produce changes in Po.tot (Fig. 3D) in mid diaphysis. In distal diaphysis neither α 9 nor α 10KO showed any significant alterations (Fig. S1D). Also the Ct.Th was not changed in α 9 and α 10KO for both cortical regions (Figs. 3E and S1E) which was verified by μ CT images (Fig. 3G–H). TMD was significantly decreased in α 9KO of both regions (mid diaphysis 1.33 \pm 0.01 g/cm³, distal diaphysis 1.20 \pm 0.01 g/cm³) compared to α 9WT (mid diaphysis 1.37 \pm 0.02 g/cm³, distal diaphysis 1.23 \pm 0.02 g/cm³, each *p* < 0.01, Figs. 3F and S1F) while α 10KO was not affected.

3.4. Microarchitecture of trabecular bone

The microstructure of the trabecular bone of right femur and vertebra L1 was scanned with μ CT and typical parameters for cancellous bone were calculated (Fig. 4). The relative bone volume (BV/TV) of femur showed no significant alterations for α 9 and α 10KO compared to their WT controls (Fig. 4A). The Tb.Th was significantly declined in α 9KO (41 \pm 2 μ m) compared to α 9WT (44 \pm 1 μ m, *p* < 0.01) whereas no affect in α 10KO was observed (Fig. 4B). Regarding Tb.Sp no changes were found for α 9KO and WT while we measured an increase for α 10KO (0.24 \pm 0.014 mm) compared to α 10WT (0.22 \pm 0.018 mm, *p* < 0.01, Fig. 4C). The relative bone surface (BS/BV, 96.60 \pm 3.19 mm⁻¹), Tb.PF (31.03 \pm 2.39 mm⁻¹) as well as the SMI (2.12 \pm 0.07) was significantly increased in α 9KO compared to α 9WT (BS/BV 91.41 \pm 1.86 mm⁻¹, *p* < 0.01; Tb.PF 27.13 \pm 1.24 mm⁻¹, *p* < 0.05; SMI 2.02 \pm 0.05, *p* < 0.05; Fig. 4D–F). In accordance with these results, values of Tb.Pf (7.21 \pm 1.66 mm⁻¹) and SMI (1.06 \pm 0.09) were increased in vertebrae of α 9KO compared to α 9WT (Tb.Pf 3.96 \pm 1.90 mm⁻¹, SMI 0.79 \pm 0.14, each *p* < 0.05, Fig. 4E–F). Regarding α 10 mice, no significant alterations were determined for BS/BV (Fig. 4D) and Tb.Pf (Fig. 4E) of femur as well as vertebrae (Fig. 4G–H). The SMI was significantly increased for α 10KO (1.69 \pm 0.09) compared to α 10WT (1.58 \pm 0.12, *p* < 0.001, Fig. 4F) in femur whereas SMI of vertebrae showed no significant differences (Fig. 4H). In addition, we found no significant changes in BV/TV, Tb.Th, Tb.Sp, BS/BV and BMD of vertebrae as well as of BMD of femur (Fig. S2E, F). To visualize the alteration in trabecular microstructure, a 3D model was generated (Fig. 4I–J) where trabecular size was color coded (blue: app. 10–20 μ m, green: app. 30–50 μ m, red: app. 60–100 μ m).




Fig. 2. Bone strength. Measurement of (A) body weight, (B) bending stiffness, (C) maximal breaking force of knockout mice of the $\alpha 9$ and $\alpha 10$ subunits of nicotinic acetylcholine receptors ($\alpha 9$ KO, $\alpha 10$ KO) and their corresponding wild type mice (WT). * $p \leq 0.05$; *** $p \leq 0.001$.





Fig. 3. Microarchitecture of mid diaphyseal femur cortex. Calculation of (A) cortical bone area (Ct.Ar), (B) total cross-sectional area inside the periosteal envelope (Tt.Ar), (C) cortical area fraction (Ct.Ar/Tt.Ar), (D) total porosity (Po.tot), (E) 3-dimensional cortical thickness (Ct.Th 3D), (F) tissue mineral density (TMD), and 2D picture of μ CT scan of (G) knockout mice of nicotinic acetylcholine receptor subunit $\alpha 9$ ($\alpha 9$ KO) and (H) the corresponding wild type mice ($\alpha 9$ WT). $\alpha 10$ KO: knockout mice of nicotinic acetylcholine receptor subunit $\alpha 10$; $\alpha 10$ WT: corresponding wild type mice of $\alpha 10$ KO. * $p \leq 0.05$; ** $p \leq 0.01$. Scale bar: 400 μ m.

3.5. Osteoblasts

Changes in osteoblast activity were either evaluated by real-time RT-PCR of typical osteoblast markers or using histological and

subsequent histomorphometrical methods. ALP, one of the most prominent enzymes of osteoblast hydroxyapatite synthesis, was stained by enzyme histochemistry with a deep violet labeling of osteoblasts mostly situated at the trabecular surface. In addition, the violet ALP staining




Fig. 4. Microarchitecture of trabecular bone. Determination of (A) bone volume fraction (BV/TV), (B) trabecular thickness (Tb.Th), (C) trabecular separation (Tb.Sp), (D) specific bone surface (BS/BV), (E) trabecular pattern factor (Tb.Pf), (F) structure model index (SMI) of right distal femur and (G) Tb.Pf, (H) SMI of vertebrae L1, (I) 3D-color coded model of trabecular thickness of α 9KO and (J) α 9WT distal femur metaphysis. α 9KO: knockout mice of nicotinic acetylcholine receptor subunit α 9; α 10KO: knockout mice of nicotinic acetylcholine receptor subunit α 10; α 9WT: corresponding wild type mice of α 9KO; α 10WT: corresponding wild type mice of α 10KO. * $p \leq 0.05$; ** $p \leq 0.01$; *** $p \leq 0.001$. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

was also found in secreted vesicles of osteoblasts localized in osteoid and woven bone. Interestingly, in α 9KO and α 9WT (not shown) only a low amount of ALP positive staining product was found (Fig. 5A) whereas in α 10KO and WT a high number of ALP positive structures were observed (Fig. 5B). Here we identified single osteoblast covering the trabecular bone (arrow in Fig. 5B). Subsequent histomorphometrical calculation of the ALP.Pm/B.Pm did not show significant changes in α 9 and α 10KO compared to their corresponding WT mice (Fig. 5C). In accordance with ALP histology (Fig. 5A–B) ALP.Pm/B.Pm was low in α 9KO ($8.81 \pm 4.27\%$) and WT ($17.84 \pm 11.62\%$) and much higher in

α 10KO ($90.33 \pm 7.39\%$) and α 10WT ($79.31 \pm 21.77\%$, Fig. 5C). At the mRNA level, ALP was significantly decreased in α 10KO (-6.16 ± -0.59 Δ CP) compared to α 10WT (-5.57 ± -0.36 Δ CP, $p < 0.05$) but no regulation was found for α 9KO (-6.41 ± -0.54 Δ CP) and WT (-6.02 ± -0.47 Δ CP, Fig. 5D). As a second marker, measurement of mRNA expression levels of Coll1 α 1 revealed a significant decrease in α 9KO (-1.38 ± -0.68 Δ CP) compared to α 9WT (-0.68 ± -0.35 Δ CP, $p < 0.05$) whereas no significant differences were found for α 10 (Fig. 5E). Since Coll1 α 1 holds the highest proportion of organic substances of bone matrix we decided to perform an




Fig. 5. Osteoblasts. Alkaline phosphatase (ALP) enzyme histochemical staining of (A) $\alpha 9$ WT and (B) $\alpha 10$ KO. Arrow in B marks single ALP positive osteoblasts. Scale bar: 20 μ m. (C) Histomorphometrical calculation of relative ALP perimeter (ALP.Pm/B.Pm) using the ALP enzyme histochemical stainings. mRNA expression analysis of (D) ALP and (E) collagen 1 $\alpha 1$ (Col1 $\alpha 1$) by means of real-time RT-PCR. Measurement of relative osteoid area (O.Ar/B.Ar) by means of histomorphometrical analysis of Kossa-van-Gieson staining. $\alpha 9$ KO: knockout mice of nicotinic acetylcholine receptor subunit $\alpha 9$; $\alpha 10$ KO: knockout mice of nicotinic acetylcholine receptor subunit $\alpha 10$; $\alpha 9$ WT: corresponding wild type mice of $\alpha 9$ KO; $\alpha 10$ WT: corresponding wild type mice of $\alpha 10$ KO. * $p \leq 0.05$.

additional von Kossa-van-Gieson staining to determine the relative osteoid area (O.Ar/B.Ar) by means of histomorphometry. The corresponding results showed neither a regulation of $\alpha 9$ nor of $\alpha 10$ KO compared to their WT (Fig. 5F).

In addition to these results regarding osteoblasts in adult murine bone, we evaluated osteoblasts *in vitro* that were harvested from neonatal $\alpha 9$ KO and $\alpha 9$ WT mice to answer the question whether the $\alpha 9$ KO osteoblasts are fully functional. Bone mineralization was investigated by ALP activity in relation to total protein. No significant changes were measured for $\alpha 9$ KO (923 ± 307 IU/g) compared to $\alpha 9$ WT (793 ± 213 IU/g, $p = 0.351$, Fig. 6 A) in osteogenic differentiation medium. As sign of successful osteogenic differentiation we measured a significant increase in ALP activity of $\alpha 9$ KO cells in osteogenic medium compared to standard cell culture medium (570 ± 249 IU/g, $p < 0.001$). In accordance, matrix deposition of collagen type 1 and 3 analyzed by Picro-Sirius-Red staining followed by histomorphometry was not significantly modified in $\alpha 9$ KO (collagen type 1: $14.51 \pm 3.77\%$, collagen type 3: $3.66 \pm 1.26\%$) compared to $\alpha 9$ WT (collagen type 1: $13.15 \pm 3.87\%$, collagen type 3: $4.41 \pm 1.89\%$, $p = 0.34$; Fig. 6B) in osteogenic differentiation medium. In standard cell culture medium the osteoblast did not deposit any collagen type 1 and 3.




Fig. 6. Cell culture experiments of neonatal osteoblasts. (A) ALP activity per total protein of $\alpha 9$ KO and $\alpha 9$ WT cultured in osteogenic differentiation medium (OM) and standard medium (SM). (B) Histomorphometrical analysis of Picro-Sirius-Red positive stained area of $\alpha 9$ KO and $\alpha 9$ WT osteoblasts in osteogenic differentiation medium. $\alpha 9$ KO: knockout mice of nicotinic acetylcholine receptor subunit $\alpha 9$; $\alpha 9$ WT: corresponding wild type mice of $\alpha 9$ KO. Col 1: collagen type 1, Col 3: collagen type 3. *** $p \leq 0.001$.

4.41 \pm 1.89%, $p = 0.34$; Fig. 6B) in osteogenic differentiation medium. In standard cell culture medium the osteoblast did not deposit any collagen type 1 and 3.

3.6. Osteocytes and cell-contacts

Osteocytes are linked with each other by gap junctions that can be identified by its characteristic protein Cx43. By means of real-time RT-PCR we measured a significant decrease in Cx43 expression in $\alpha 9$ KO (KO: -7.07 ± -0.62 Δ CP, WT: -6.38 ± -0.49 Δ CP, $p < 0.028$) whereas subunit $\alpha 10$ KO (KO: -6.71 ± -0.65 Δ CP, WT: -6.32 ± -0.25 Δ CP) showed no regulation at the mRNA level (Fig. 7A). Using a polyclonal antibody against Cx43 we found a distinct macular and fibrillary staining around the osteocytes in trabecular and cortical bone (Fig. 7D). We supposed that this labeling identifies the osteocytic processes and gap junctions between the dendrites. In addition, the cytoplasm of some of the osteocytes, osteoblasts, osteoclasts, and hematopoietic precursors (e.g. megakaryocytes) were also labeled with a moderate intensity by Cx43 antibody as well as some vessels and




Fig. 7. Osteocytes. Determination of mRNA expression of (A) connexin 43 (Cx43), (B) *SOST*, and (C) histomorphometrical quantification of sclerostin immunopositive osteocytes per bone area (Scl.Ot/B.Ar). Immunohistochemical labeling of osteocytes and their dendrites with (D) antiserum against Cx43 (exemplary picture of $\alpha 9$ KO) and (E) sclerostin (exemplarily for $\alpha 10$ WT). $\alpha 9$ KO: knockout mice of nicotinic acetylcholine receptor subunit $\alpha 9$; $\alpha 10$ KO: knockout mice of nicotinic acetylcholine receptor subunit $\alpha 10$; $\alpha 9$ WT: corresponding wild type mice of $\alpha 9$ KO; $\alpha 10$ WT: corresponding wild type mice of $\alpha 10$ KO. * $p \leq 0.05$. Scale bar: 20 μ m.

capillaries.

Since the most typical marker for osteocytes is sclerostin, we also analyzed the mRNA expression of *SOST*, the sclerostin gene. No expression level change of *SOST* was detected ($\alpha 9$ KO: -7.48 ± -0.32 $-\Delta$ CP, WT: -7.73 ± -0.33 $-\Delta$ CP; $\alpha 10$ KO: -7.57 ± -0.53 $-\Delta$ CP, WT: -7.25 ± -0.41 $-\Delta$ CP, Fig. 7B). Immunohistochemically only some of the osteocytes were labeled while others remained blank. Often the positive labeled osteocytes were localized in the direct neighborhood of negative osteocytes (Fig. 7E). Quantification of the number of sclerostin positive osteocytes per bone area (Scl.Ot/B.Ar) did not reveal significant changes (Fig. 7C). Using TEM we investigated the ultrastructure of osteocytes and determined a highly significant increase in degenerating and dying osteocytes of $\alpha 9$ KO compared to $\alpha 9$ WT ($p < 0.001$, Fig. 8). For quantification we used a score comprising three subdivisions. In $\alpha 9$ KO, 18.43% cells of osteocytes were scored as 1, 56.47% were scored 2, and 25.1% were scored 3. In the $\alpha 9$ WT group 41.24% cells scored 1, 47.46% scored 2, 11.3% scored 3 (Fig. 8D). No changes were observed for $\alpha 10$ KO compared to $\alpha 10$ WT ($\alpha 10$ KO score 1: 28.43%, score 2: 51.96%, score 3: 19.61%, $\alpha 10$ WT score 1: 18.42%, score 2: 63.16%, score 3: 18.42%, Fig. 8D).

3.7. Osteoclasts

Osteoclasts were stained by TRAP and analyzed histomorphometrically. No significant changes were detected for N.Oc/B.Pm ($\alpha 9$ KO: 5.81 ± 2.07 mm^{-1} WT: 4.52 ± 2.58 mm^{-1} , $\alpha 10$ KO: 5.42 ± 2.52 mm^{-1} WT: 7.53 ± 2.21 mm^{-1} , Fig. 9A) as well as for Oc.Pm/B.Pm ($\alpha 9$ KO: 10.43 ± 4.54 WT: 9.23 ± 7.25 , $\alpha 10$ KO: 8.25 ± 5.89 WT: 15.29 ± 6.85 , Fig. 9B). We investigated the mRNA expression of Cathepsin K (CtsK), the typical degrading enzyme of osteoclasts. No significant changes were measured for CtsK expression in $\alpha 9$ KO or $\alpha 10$ KO mice ($\alpha 9$ KO: -2.50 ± -0.60 $-\Delta$ CP, WT:

-2.46 ± -0.37 $-\Delta$ CP; $\alpha 10$ KO: -2.15 ± -0.48 $-\Delta$ CP, WT: -1.93 ± -0.38 $-\Delta$ CP, Fig. 9C).

4. Discussion

In the present study we analyzed the bone tissue of $\alpha 9$ and $\alpha 10$ nAChR subunit KO mouse strains, and compared them to their individual WT mouse strain. The advantage of using KO mice with deletion of single genes is the detailed picture that can be generated about the impact of a single protein in strength and structure of bone as well as presence of bone cells and regulation of typical bone markers. Biomechanical measurements showed a decrease in bending stiffness and maximal breaking force of $\alpha 9$ KO compared to their corresponding wild type mice. In contrast, KO of the $\alpha 10$ subunit showed no significant alterations. Bending stiffness and maximal breaking force were measured by a three-point bending test. Reduced strength is often combined with reduced mineralization and therefore commonly found in osteopenic and osteoporotic bone. μ CT analysis of cortical bone showed significantly reduced TMD in both diaphysal regions of the left femur in $\alpha 9$ KO mice compared to their corresponding wild type. Tt.Ar and Ct.Ar of mid-diaphysal and distal region (Fig. S1) were significantly decreased in the $\alpha 9$ KO setting. Noteworthy, the ratio of Ct.Ar/Tt.Ar was not altered. With a view to unchanged Ct.Ar/Tt.Ar ratio and reduced body weight of $\alpha 9$ KO, one may speculate that impaired biomechanical properties are caused by smaller long bones. However, decreased mineralization and altered porosity imply alterations in $\alpha 9$ KO bone strength caused by abnormal structure and modified bone matrix.

On the microstructural level of cortical bone a significant reduction of porosity was measured in $\alpha 9$ KO compared to $\alpha 9$ WT. Three hierarchical levels of porosity occur in cortical bone: (i) Collagen-hydroxyapatite porosity that denotes the very small space (in humans: order




Fig. 8. Transmission electron microscopy (TEM) of osteocytes. (A) Osteocyte of $\alpha 9$ KO with enlarged pericellular space (star), folding of the cytoplasm membrane (arrow), and enlarged space between the two membranes of nucleus (arrow head). (B) Healthy osteocyte of $\alpha 9$ WT. (C) Scoring results with significantly increased number of degenerated and dying osteocytes in $\alpha 9$ KO compared to $\alpha 9$ WT while no significant difference was measured for $\alpha 10$ KO and WT. Score 1: healthy, score 2: degenerating, score 3: dying osteocytes. Scale bar: 2 μ m.

of 0.01 μ m in radius) between the collagen fibers and hydroxyapatite crystals which is usually filled with bound fluids. (ii) Lacunar-canalicular porosity that comprises the pericellular space of osteocytes and their processes which in humans is on the order of 0.1 μ m in radii [29]. Neither the collagen-hydroxyapatite and the lacunar-canalicular porosity were analyzed using μ CT because of the small size of the pores and limitation of the resolution of our μ CT analyses at isotropic voxel size of 5.69 μ m. We investigated (iii) vascular porosity in cortical mid and distal diaphysis. The vascular porosity is defined by the system of Haversian and Volkmann canals in human bone including vessels, nerve fibers, and several cell types (e.g. osteoblasts, macrophages, osteoclasts). Mice cortical bone does not form osteons with Haversian canals [30]. Here, vessels are often found in erosion tunnels and lacunae. The vascular network in rodents is built in series whereas it is organized in parallel in humans [29]. Depending on the mouse strain the vascular porosity reaches values of 0.8 ± 0.2 to $4.8 \pm 1.5\%$ [31] which is in accordance to our results of $\alpha 9$ WT and $\alpha 10$ mice. It is noteworthy that the vascular porosity of $\alpha 9$ KO was significantly reduced (average of $0.06 \pm 0.08\%$). The nAChR subunit $\alpha 10$ is expressed by many locations within the vascular systems whereas subunit $\alpha 9$ shows a distinct expression pattern with occurrence in vascular smooth muscle and endothelial cells in rat and human placenta [32] but absence in e.g. truncus pulmonalis, aorta thoracica [33]. To our knowledge it is not known whether the bone vascular system express nAChR subunits $\alpha 9$ and 10. However, application of nicotine leads to dilation in the most vascular systems [34] whereas in bone it enhances vascular constriction [35]. Since the pharmacological profile of $\alpha 9\alpha 10$ does not resemble the

typical nAChR [36], not only the presence of these subunits but also their functional role remains unknown in the bone vascular system. In addition to vascular walls, the vascular pores also contain nerve fibers, mesenchymal stem cells, osteoblast precursors and osteoblasts. Regarding nerve fibers, knowledge about $\alpha 9\alpha 10$ nAChR is still limited even though the presence of both subunits in several brain regions was recently published [10].

Besides analyzing bone cortex, μ CT was used for investigations of the trabecular bone of femur and vertebrae. $\alpha 9$ KO mice demonstrated an increase in Tb.Pf, SMI and BS/BV while Tb.Th was reduced. The decline in Tb.Th is one of the typical characteristics of osteopenic and osteoporotic bone. In osteopenia and osteoporosis reduced Tb.Th is usually combined with a decrease in BV/TV and Tb.N and increase in Tb.Sp which we did not detect in $\alpha 9$ KO compared to $\alpha 9$ WT. Thus, we suggest that $\alpha 9$ KO mice do not develop an osteoporotic bone phenotype. This hypothesis is confirmed by the missing regulation of BMD (Fig. S2). However, small perforations and intratrabecular connectivity cannot be calculated by these values but by the Tb.Pf [37]. Well connected trabeculae possess a low Tb.Pf in contrast to more convex formed trabeculae characterized by a greater Tb.Pf. In 3D networks, a high Tb.Pf displays a less connected pattern as determined in spongy bone of postmenopausal females [37]. Thus, $\alpha 9$ KO mice showed initial signs of an early stage of bone loss. The dimension free SMI was also significantly increased in $\alpha 9$ KO compared to $\alpha 9$ WT. An SMI value of 0 describes an ideal plate-like structure of the 3D network of trabeculae and a value of 3 an ideal rod-like structure [38]. In the case of $\alpha 9$ KO the trabeculae were arranged in a more rod-like structure than in $\alpha 9$ WT. In




Fig. 9. Osteoclasts. Histomorphometrical calculation of TRAP stainings of (A) number of osteoclasts per bone perimeter (N.Oc/B.Pm), (B) relative osteoclast perimeter (Oc.Pm/B.Pm) and (C) mRNA expression of Cathepsin K (CtsK) by means of real-time RT-PCR. $\alpha 9$ KO: knockout mice of nicotinic acetylcholine receptor subunit $\alpha 9$; $\alpha 10$ KO: knockout mice of nicotinic acetylcholine receptor subunit $\alpha 10$; $\alpha 9$ WT: corresponding wild type mice of $\alpha 9$ KO; $\alpha 10$ WT: corresponding wild type mice of $\alpha 10$ KO.

a murine model of senile osteoporosis, an increase in SMI was measured compared to healthy control mice [39]. Therefore, SMI confirms Tb.Pf results indicating the start of functional bone loss in $\alpha 9$ KOs. However, the SMI is critically discussed as a value that can be artificially depressed [40].

Reduced bone mass is often caused by increased enzymatic activity and/or number of osteoclasts. Here, we analyzed osteoclasts by TRAP staining and subsequent histomorphometrical calculation and real-time RT-PCR for CtsK, one of the osteoclastic enzymes which is responsible for degradation of the organic bone matrix. None of the investigated parameters showed any alterations in $\alpha 9$ and $\alpha 10$ KO mice compared to their corresponding wild type controls. Since osteoclasts and osteoblast are two sides of one coin we decided to next analyze bone forming osteoblasts of neonatal $\alpha 9$ KO, $\alpha 9$ WT and in adult $\alpha 9$ and $\alpha 10$ mice. Neonatal $\alpha 9$ KO osteoblasts in vitro were not significantly altered compared to $\alpha 9$ WT in osteogenic differentiation as well as standard cell culture medium by means of ALP assay and Picro-Sirius-Red staining. Thus, $\alpha 9$ KO osteoblasts seemed to be fully functional. To examine adult osteoblasts we used total bones instead of isolated cells. Regarding hydroxyapatite synthesis and mineralization, we analyzed ALP by means of histology, histomorphometry, real-time RT-PCR, and Kossav-Gieson stained histological sections followed by calculation of the relative osteoid area (O.Ar/B.Ar). None of these parameters were changed in $\alpha 9$ KO except for significantly reduced mRNA expression of collagen (Col1 $\alpha 1$) of $\alpha 9$ KOs compared to $\alpha 9$ WTs. Subcutaneous application of nicotine provokes less compact arranged collagen bundles in skin of male adult guinea pigs with enlarged space between the bundles which increases in correlation to enhanced nicotine concentrations [41]. In addition, nicotine administration leads to an increase in collagen type 1 mRNA expression in skin [42] as well as in lung [43] where the stimulatory effect was inhibited in nAChR subunit alpha 7 ($\alpha 7$ KO) knockout mice [44]. In bone we could not determine a regulation of col1 $\alpha 1$ mRNA expression in $\alpha 7$ KO [44] and therefore involvement of nAChR in collagen synthesis might be tissue specific. nAChR subunit $\alpha 3$ implies a part of the nicotine-collagen pathway in skin [42] whereas nAChR subunit $\alpha 9$ might be responsible for it in bone. Alterations in collagen fiber arrangement, secreted collagen products in blood serum as well as cellular regulation on mRNA and protein level were found in animals of osteoporosis models as well as in samples of patients with osteoporosis [45–47]. Thus, the decrease in Col1 $\alpha 1$ mRNA expression in bone of $\alpha 9$ KO support our results of μ CT (Tb.Pf, SMI) and biomechanical measurements (bending stiffness, maximal breaking force) regarding the first phases of bone mass reductions by means of structural alterations.

At the mRNA level, we measured a reduction of Cx43 expression in $\alpha 9$ KO compared to $\alpha 9$ WT. Cx43 is a transmembrane protein which is involved in hexameric hemichannels (connexons) that can be combined with connexons of other cells by formation of gap junctions [48]. Cx43 is the most abundant connexin in bone. It is found in osteoblasts, osteocytes, and osteoclasts [48]. Using immunohistochemistry we detected Cx43 amongst others in osteoblasts where its involvement in proper fracture healing was reported for cell type specific Cx43 KO mice. Global Cx43 KO mice exhibited a delayed osteoblast differentiation and bone mineralization [49]. However, intensive immunopositive structures in $\alpha 9$ KO, $\alpha 10$ KO and WT were found in vessels, osteocytic dendrites and the gap junctions between the osteocytes as shown by a strong macular and thin fibrillary staining around osteocytes. Deletion of osteocytic Cx43 resulted in an enhanced apoptosis of osteocytes, faster aging, reduced cortical area fraction and cortical bone material strength, and increased periosteal bone formation [49]. In analogy with osteocytic Cx43 deletion, we found a reduced strength in cortical bone as measured by biomechanical tests in $\alpha 9$ KO. In skin, nAChR $\alpha 9$ is involved in cell-cell as well as cell-matrix adhesion [13]. Blocking of nAChR $\alpha 9$ leads to skin blisters and faulty regulation of keratinocyte adhesion [50]. Thus, it is possible that deletion of nAChR subunit $\alpha 9$ is implicated in defects in cell-cell contacts of osteocytes.

Osteocytes have an important role in defect healing as well as remodeling. They detect the mechanical strain, regulate bone formation via osteoblasts and bone resorption via osteoclasts. One of the most important molecules of osteocytes involved in these processes is sclerostin which is nearly exclusively synthesized by osteocytes and its up-regulation inhibits bone formation [51]. In $\alpha 9$ and $\alpha 10$ KO mice, we did not find an altered expression of sclerostin at mRNA or protein level. We observed immunohistochemical labeling for sclerostin in some osteocytes while neighboring osteocytes showed no immunolabeling. This somehow inconsistent staining pattern was also described by Robling et al. and is considered to be normal for osteocytes because mechanical loading is different for every osteocyte even if they are arranged in the same trabeculae [52].

On the ultrastructural level, we observed a reduced number of healthy osteocytes and a higher number of degenerating and dying osteocytes in $\alpha 9$ KO compared to $\alpha 9$ WT. Dying osteocytes express and secrete factors such as receptor of nuclear factor kappa B ligand (RANKL) which stimulates osteoclastogenesis and leads to chemotactic movement of osteoclasts towards damaged osteocytes where bone matrix will be degraded [51]. Thus, the reduction of Cx43 together with the ultrastructural signs of degeneration in osteocytes might be a significant reason for the biomechanical weakness, the alterations of typical μ CT parameters like SMI and Tb.Pf. No significant differences in ultrastructure were found for $\alpha 10$ KO compared to $\alpha 10$ WT. Therefore, it would be interesting to investigate the bone status of the recently generated double KO mice of $\alpha 9\alpha 10$ nAChR [53] and bone cell specific KO mice in an up-coming study. One limitation of our study is the usage of constitutive gene KO that could have systemic impacts, e.g. input of the nervous system that might interfere with typical effects in bone. It may also be of interest in future studies to perform functional assays for e.g. ALP, TRAP, and collagen of bone and serum.

Recently, the expression of subunits $\alpha 9$ and $\alpha 10$ was reported in several brain regions [10] where they might be involved in the regulation of behavior and activity. Impaired physical activity connected with muscle degeneration and loss of bone mass could explain the alteration of $\alpha 9$ KO bone status. To test this, a hang test was performed on $\alpha 9$ KO mice, but did not find significant changes compared to the $\alpha 9$ WTs. The brain secretome includes several hormones that strongly influence bone homeostasis and osteocyte function. Mohammadi et al. (2017) described a dysregulation of the hypothalamus-pituitary-gland axis by disruption of the circadian rhythm in $\alpha 9\alpha 10$ KO that altered hormone release [54] and might therefore be involved in pathological alterations of bone.

5. Conclusions

In summary, we reported here the reduced biomechanical strength, decreased cortical TMD and alterations in trabecular microarchitecture in nAChR $\alpha 9$ KO mice that mirror the characteristic properties of an osteopenic bone. In addition, we detected reduced expression of Col1 $\alpha 1$ and Cx43 as well as a higher number of degenerated and dying osteocytes in $\alpha 9$ KO compared to $\alpha 9$ WT. The nAChR $\alpha 9$ subunit seems to be involved in regulation of matrix formation by osteoblasts and the cell-cell contacts of osteocytes. Therefore, lack of activity of nAChRs containing $\alpha 9$ subunits might modify the osteocytic regulation of bone remodeling followed by alterations in bone phenotype that result in the bony characteristics of osteopenia.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bone.2018.11.003>.

Disclosures

All authors state that they have no conflict of interest.

Acknowledgments

The authors thank Ivonne Bergen, Olga Dakischew, Gunhild Martels, and Ida Oberst for skillful technical assistance and Dr. Ursula Sommer for TEM analysis. This study was supported by German Research Society (DFG SFB/TRR 79 projects B7, Z3 to VK, KSL and MK as well as KR 4338/1-1 to GKC) and grant support NIH R21DC015124 to DEV. The UMMC Animal Behavior Core is funded through an NIH Institutional Development Award (IDeA) from the National Institute of General Medical Sciences (P30 GM103328). The study is part of the thesis of L. Baumann.

References

- P. Mandl, S. Hayer, T. Karonitsch, P. Scholze, D. Gyori, D. Sykourti, S. Bluml, A. Mocsai, G. Poor, S. Huck, J.S. Smolen, K. Redlich, Nicotinic acetylcholine receptors modulate osteoclastogenesis, *Arthritis Res. Ther.* 18 (2016) 63.
- A. Bajayo, A. Bar, A. Denes, M. Bachar, V. Kram, M. Attar-Namdar, A. Zallone, K.J. Kovacs, R. Yirmiya, I. Bab, Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual, *Proc. Natl. Acad. Sci. U. S. A.* 109 (2012) 15455–15460.
- K.S. Lips, M. Kneffel, F. Willscheid, F.M. Mathies, M. Kampschulte, S. Hartmann, I. Panzer, L. Durselen, C. Heiss, V. Kauschke, Altered ultrastructure, density and cathepsin K expression in bone of female muscarinic acetylcholine receptor M3 knockout mice, *Int. Immunopharmacol.* 29 (2015) 201–207.
- D. Kalamida, K. Poulas, V. Avramopoulou, E. Fostieri, G. Lagoumintzis, K. Lazaridis, A. Sideri, M. Zouridakis, S.J. Tzartos, Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity, *FEBS J.* 274 (2007) 3799–3845.
- A.B. Elgoyhen, D.E. Vetter, E. Katz, C.V. Rothlin, S.F. Heinemann, J. Boulter, $\alpha 10$: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells, *Proc. Natl. Acad. Sci. U. S. A.* 98 (2001) 3501–3506.
- F. Sgard, E. Charpantier, S. Bertrand, N. Walker, D. Caput, D. Graham, D. Bertrand, F. Besnard, A novel human nicotinic receptor subunit, $\alpha 10$, that confers functionality to the $\alpha 9$ -subunit, *Mol. Pharmacol.* 61 (2002) 150–159.
- H.K. Romero, S.B. Christensen, L. Di Cesare Mannelli, J. Gajewiak, R. Ramachandra, K.S. Elmslie, D.E. Vetter, C. Ghelardini, S.P. Iadonato, J.L. Mercado, B.M. Olivera, J.M. McIntosh, Inhibition of $\alpha 9 \alpha 10$ nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain, *Proc. Natl. Acad. Sci. U. S. A.* 114 (2017) E1825–E1832.
- H. Peng, R.L. Ferris, T. Matthews, H. Hiel, A. Lopez-Albaiteiro, L.R. Lustig, Characterization of the human nicotinic acetylcholine receptor subunit alpha (alpha) 9 (CHRNA9) and alpha (alpha) 10 (CHRNA10) in lymphocytes, *Life Sci.* 76 (2004) 263–280.
- A. Hecker, M. Kullmar, S. Wilker, K. Richter, A. Zakrzewicz, S. Atanasova, V. Mathes, T. Timm, S. Lerner, J. Klein, A. Kaufmann, S. Bauer, W. Padberg, W. Kummer, S. Janciuskiene, M. Fronius, E.K. Schweda, G. Lochnit, V. Grau, Phosphocholine-modified macromolecules and canonical nicotinic agonists inhibit ATP-induced IL-1 β release, *J. Immunol.* 195 (2015) 2325–2334.
- O. Lykhus, L.P. Voytenko, K.S. Lips, I. Bergen, G. Krasteva-Christ, D.E. Vetter, W. Kummer, M. Skok, Nicotinic acetylcholine receptor $\alpha 9$ and $\alpha 10$ subunits are expressed in the brain of mice, *Front. Cell. Neurosci.* 11 (2017) 282.
- C.S. Chen, C.H. Lee, C.D. Hsieh, C.T. Ho, M.H. Pan, C.S. Huang, S.H. Tu, Y.J. Wang, L.C. Chen, Y.J. Chang, P.L. Wei, Y.Y. Yang, C.H. Wu, Y.S. Ho, Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins, *Breast Cancer Res. Treat.* 125 (2011) 73–87.
- C.H. Lee, C.S. Huang, C.S. Chen, S.H. Tu, Y.J. Wang, Y.J. Chang, K.W. Tam, P.L. Wei, T.C. Cheng, J.S. Chu, L.C. Chen, C.H. Wu, Y.S. Ho, Overexpression and activation of the $\alpha 9$ -nicotinic receptor during tumorigenesis in human breast epithelial cells, *J. Natl. Cancer Inst.* 102 (2010) 1322–1335.
- A.I. Chernyavsky, J. Arredondo, D.E. Vetter, S.A. Grando, Central role of $\alpha 9$ acetylcholine receptor in coordinating keratinocyte adhesion and motility at the initiation of epithelialization, *Exp. Cell Res.* 313 (2007) 3542–3555.
- A. Chikova, S.A. Grando, Naturally occurring variants of human A9 nicotinic receptor differentially affect bronchial cell proliferation and transformation, *PLoS One* 6 (2011) e27978.
- L. Luo, T. Bennett, H.H. Jung, A.F. Ryan, Developmental expression of $\alpha 9$ acetylcholine receptor mRNA in the rat cochlea and vestibular inner ear, *J. Comp. Neurol.* 393 (1998) 320–331.
- A. Zablotti, O. Dakischew, K. Trinkaus, S. Hartmann, G. Szalay, C. Heiss, K.S. Lips, Regulation of acetylcholine receptors during differentiation of bone mesenchymal stem cells harvested from human reaming debris, *Int. Immunopharmacol.* 29 (2015) 119–126.
- M. En-Nosse, S. Hartmann, K. Trinkaus, V. Alt, B. Stigler, C. Heiss, O. Kilian, R. Schnettler, K.S. Lips, Expression of non-neuronal cholinergic system in osteoblast-like cells and its involvement in osteogenesis, *Cell Tissue Res.* 338 (2009) 203–215.
- X. Che, J. Guo, L. Wang, C. Miao, L. Ge, Z. Tian, J. Wang, Involvement of the nonneuronal cholinergic system in bone remodeling in rat midpalatal suture after rapid maxillary expansion, *Biomed. Res. Int.* 2016 (2016) 8106067.
- J. Guo, L. Wang, H. Xu, X. Che, Expression of non-neuronal cholinergic system in maxilla of rat in vivo, *Biol. Res.* 47 (2014) 72.
- Y. Ma, X. Li, J. Fu, Y. Li, L. Gao, L. Yang, P. Zhang, J. Shen, H. Wang, Acetylcholine affects osteocytic MLO-Y4 cells via acetylcholine receptors, *Mol. Cell. Endocrinol.* 384 (2014) 155–164.
- D.E. Vetter, E. Katz, S.F. Maison, J. Taranda, S. Turcan, J. Ballestero, M.C. Liberman, A.B. Elgoyhen, J. Boulter, The $\alpha 10$ nicotinic acetylcholine receptor subunit is required for normal synaptic function and integrity of the olivocochlear system, *Proc. Natl. Acad. Sci. U. S. A.* 104 (2007) 20594–20599.
- D.E. Vetter, M.C. Liberman, J. Mann, J. Barhanin, J. Boulter, M.C. Brown, J. Saffiote-Kolman, S.F. Heinemann, A.B. Elgoyhen, Role of $\alpha 9$ nicotinic ACh receptor subunits in the development and function of cochlear efferent innervation, *Neuron* 23 (1999) 93–103.
- V. Rontgen, R. Blakytyn, R. Matthys, M. Landauer, T. Wehner, M. Gockelmann, P. Jermendy, M. Amling, T. Schinke, L. Claes, A. Ignatius, Fracture healing in mice under controlled rigid and flexible conditions using an adjustable external fixator, *J. Orthop. Res.* 28 (2010) 1456–1462.
- V. Kauschke, M. Kneffel, W. Floel, S. Hartmann, M. Kampschulte, L. Durselen, A. Ignatius, R. Schnettler, C. Heiss, K.S. Lips, Bone status of acetylcholinesterase-knockout mice, *Int. Immunopharmacol.* 29 (2015) 222–230.
- M.L. Boussein, S.K. Boyd, B.A. Christiansen, R.E. Guldberg, K.J. Jepsen, R. Muller, Guidelines for assessment of bone microstructure in rodents using micro-computed tomography, *J. Bone Miner. Res.* 25 (2010) 1468–1486.
- R.J. van 't Hof, L. Rose, E. Bassonga, A. Daroszewska, Open source software for semi-automated histomorphometry of bone resorption and formation parameters, *Bone* 99 (2017) 69–79.
- S.E. Taylor, M. Shah, I.R. Orriss, Generation of rodent and human osteoblasts, *Bonekey Rep.* 3 (2014) 585, <https://doi.org/10.1038/bonekey.2014.80>.
- I.R. Orriss, M.O. Hajjawi, C. Huesa, V.E. MacRae, T.R. Arnett, Optimisation of the differing conditions required for bone formation in vitro by primary osteoblasts from mice and rats, *Int. J. Mol. Med.* 34 (2014) 1201–1208, <https://doi.org/10.3892/ijmm.2014.1926>.
- S.C. Cowin, L. Cardoso, Blood and interstitial flow in the hierarchical pore space architecture of bone tissue, *J. Biomech.* 48 (2015) 842–854.
- D.H. Enlow, Functions of the Haversian system, *Am. J. Anat.* 110 (1962) 269–305.
- L. Cardoso, S.P. Fritton, G. Gailani, M. Benalla, S.C. Cowin, Advances in assessment of bone porosity, permeability and interstitial fluid flow, *J. Biomech.* 46 (2013) 253–265.
- K.S. Lips, D. Bruggmann, U. Pfeil, R. Vollerthun, S.A. Grando, W. Kummer, Nicotinic acetylcholine receptors in rat and human placenta, *Placenta* 26 (2005) 735–746.
- D. Bruggmann, K.S. Lips, U. Pfeil, R.V. Haberberger, W. Kummer, Multiple nicotinic acetylcholine receptor alpha-subunits are expressed in the arterial system of the rat, *Histochem. Cell Biol.* 118 (2002) 441–447.
- N. Toda, H. Toda, Nitric oxide-mediated blood flow regulation as affected by smoking and nicotine, *Eur. J. Pharmacol.* 649 (2010) 1–13.
- J.B. Feitelson, P.P. Rowell, C.S. Roberts, J.T. Fleming, Two week nicotine treatment selectively increases bone vascular constriction in response to norepinephrine, *J. Orthop. Res.* 21 (2003) 497–502.
- J.M. McIntosh, N. Absalom, M. Chebib, A.B. Elgoyhen, M. Vincler, $\alpha 9$ nicotinic acetylcholine receptors and the treatment of pain, *Biochem. Pharmacol.* 78 (2009) 693–702.
- M. Hahn, M. Vogel, M. Pompesius-Kempa, G. Delling, Trabecular bone pattern factor—a new parameter for simple quantification of bone microarchitecture, *Bone* 13 (1992) 327–330.
- T. Hildebrand, P. Rueggsegger, Quantification of bone microarchitecture with the structure model index, *Comput. Methods Biomech. Biomed. Engin.* 1 (1997) 15–23.
- H. Chen, K.Y. Kubo, Segmental variations in trabecular bone density and microstructure of the spine in senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis, *Exp. Gerontol.* 47 (2012) 317–322.
- P.L. Salmon, C. Ohlsson, S.J. Shefelbine, M. Doube, Structure model index does not measure rods and plates in trabecular bone, *Front. Endocrinol.* 6 (2015) 162 Lausanne.
- S.A. Eltony, S.S. Ali, Histological study on the effect of nicotine on adult male guinea pig thin skin, *Anat. Cell Biol.* 50 (2017) 187–199.
- J. Arredondo, L.L. Hall, A. Ndoye, V.T. Nguyen, A.I. Chernyavsky, D. Bercovich, A. Orr-Urtreger, A.L. Beaudet, S.A. Grando, Central role of fibroblast $\alpha 3$ nicotinic acetylcholine receptor in mediating cutaneous effects of nicotine, *Lab. Invest.* 83 (2003) 207–225.
- H.S. Sekhon, J.A. Keller, B.J. Proskocil, E.L. Martin, E.R. Spindel, Maternal nicotine exposure upregulates collagen gene expression in fetal monkey lung. Association with $\alpha 7$ nicotinic acetylcholine receptors, *Am. J. Respir. Cell Mol. Biol.* 26 (2002) 31–41.
- G.W. Vicary, J.D. Ritzenthaler, T.S. Panchabhai, E. Torres-Gonzalez, J. Roman, Nicotine stimulates collagen type I expression in lung via $\alpha 7$ nicotinic acetylcholine receptors, *Respir. Res.* 18 (2017) 115.
- S. Viguet-Carrin, P. Garnero, P.D. Delmas, The role of collagen in bone strength, *Osteoporos. Int.* 17 (2006) 319–336.
- M.J. Silva, M.D. Brodt, B. Wopenka, S. Thomopoulos, D. Williams, M.H. Wassen, M. Ko, N. Kusano, Bank RA, Decreased collagen organization and content are associated with reduced strength of demineralized and intact bone in the SAMP6 mouse, *J. Bone Miner. Res.* 21 (2006) 78–88.
- D.E.S. Daghma, D. Malhan, P. Simon, S. Stotzel, S. Kern, F. Hassan, K.S. Lips, C. Heiss, T. El Khassawna, Computational segmentation of collagen fibers in bone matrix indicates bone quality in ovariectomized rat spine, *J. Bone Miner. Metab.* 36 (3) (2017) 297–306.
- L.I. Plotkin, H.M. Davis, B.A. Cisterna, J.C. Saez, Connexins and pannexins in bone

- and skeletal muscle, *Curr. Osteoporos. Rep.* 15 (2017) 326–334.
- [49] L.I. Plotkin, J.P. Stains, Connexins and pannexins in the skeleton: gap junctions, hemichannels and more, *Cell. Mol. Life Sci.* 72 (2015) 2853–2867.
- [50] V.T. Nguyen, A. Ndoye, S.A. Grando, Novel human $\alpha 9$ acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity, *Am. J. Pathol.* 157 (2000) 1377–1391.
- [51] H. Chen, T. Senda, K.Y. Kubo, The osteocyte plays multiple roles in bone remodeling and mineral homeostasis, *Med. Mol. Morphol.* 48 (2015) 61–68.
- [52] A.G. Robling, P.J. Niziolek, L.A. Baldrige, K.W. Condon, M.R. Allen, I. Alam, S.M. Mantila, J. Gluhak-Heinrich, T.M. Bellido, S.E. Harris, C.H. Turner, Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin, *J. Biol. Chem.* 283 (2008) 5866–5875.
- [53] B.J. Morley, D.F. Dolan, K.K. Ohlemiller, D.D. Simmons, Generation and characterization of $\alpha 9$ and $\alpha 10$ nicotinic acetylcholine receptor subunit knockout mice on a C57BL/6J background, *Front. Neurosci.* 11 (2017) 516.
- [54] S.A. Mohammadi, T.J. Burton, M.J. Christie, $\alpha 9$ -nAChR knockout mice exhibit dysregulation of stress responses, affect and reward-related behaviour, *Behav. Brain Res.* 328 (2017) 105–114.